ArticleThe American journal of pathology1989
Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.
Article in The American journal of pathology, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 42 citations in OpenAlex.
- Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.Familial cancer · 2004Review
- Protein glycosylation in cancer biology: an overview.Clinical molecular pathology · 1996Article
- Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.Virchows Archiv. A, Pathological anatomy and histopathology · 1993Article
- Altered expression of sialyl-Tn, Lewis antigens and carcinoembryonic antigen between primary and metastatic lesions of uterine cervical cancers.Histochemistry · 1992Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite major advances in the differential diagnosis of mesotheliomas versus adenocarcinomas, a certain percentage defy diagnosis. Several markers such as keratin, carcinoembryonic antigen, Leu-M1, milk fat globulin, and antibody against tumor-associated glycoprotein Tag-72 (B72.3) have been used to distinguish them. In this study, blood group antigens, namely Lewisx and Lewisy, known to be expressed in a number of adenocarcinomas of diverse origin were used in the differential diagnosis of 30 samples from 18 mesotheliomas and 18 primary lung adenocarcinomas. Adenocarcinomas showed strong diffuse homogeneous staining, membranous staining, or both for Lewisy in 100% of cases irrespective of differentiation. Lewisx was expressed in 78% of adenocarcinomas with a wide variation in distribution of staining. Mesotheliomas did not show the diffuse homogeneous staining pattern but showed a markedly distinctive granular staining in the cytoplasm of rare cells in 23% of Lewisy and 20% of Lewisx cases, which was interpreted as negative. In conclusion, Lewisy is a sensitive marker for adenocarcinomas in that it stains 100% of cases and is a specific marker in the differential diagnosis of mesotheliomas and adenocarcinomas.
Indexed as
Identifiers
2817084PMC1880090W1503534046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.